drug
ezetimibe
Marketedupdated 3mo agoby OEP Pharma
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- companyGlenmark Pharmaceuticals Ltd6 co-mentions · 2 sources
- tagRecall3 co-mentions · 3 sources
- drugsimvastatin2 co-mentions · 1 sources
- drugFlolipid2 co-mentions · 1 sources
- companyRemedyRepack Inc2 co-mentions · 1 sources
- drugBISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE1 co-mentions · 1 sources
- drugBISOPROLOL FUMARATE1 co-mentions · 1 sources
- drugALDACTAZIDE1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying ezetimibe
- —A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
- phase3A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
- —A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
- phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- —Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
- phase3A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
- N/AModerate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 1, 2033
~6.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- May 1, 2033formulationUS 10376470
- May 1, 2033formulationUS 10376470
- May 1, 2033formulationUS 10376470
- May 1, 2033formulationUS 10376470
- May 1, 2033formulationUS 9763885
- May 1, 2033formulationUS 9763885
- May 1, 2033formulationUS 9763885
- May 1, 2033formulationUS 9763885
- Apr 30, 2026patentUS 7612058*PED
- Oct 30, 2025method-of-use (U-1027)US 7612058
News(1)
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High CholesterolThe U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduc…fda_press · 28d ago
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that